Editorial
Subcutaneous infusionsa medical last rite Intravenous fluids have been referred to as a medical last rite.' Increasingly the routine use of intravenous fluids in patients who are dying is discouraged2; in some situations it is so actively discouraged that those who might benefit are denied them. The commonly held beliefs supporting the argument in favour of intravenous fluids are concerned with relieving the distress of thirst, fatigue, weakness, and the general suffering of terminal dehydration. Although there is no evidence to support or refute this, it is now generally accepted that the majority of dying patients derive no benefit from intravenous fluids provided attention is given to symptomatic measures such as mouth care. By contrast, it is becoming increasingly difficult to die at home, in hospital or in a specialist palliative care unit without parenteral administration of drugs. Has the subcutaneous infusion of analgesic and other drugs superseded the use of intravenous fluids as the medical and nursing last rite?
The traditional hospice approach has been marked by a reluctance to investigate patients with advanced disease and to perform what are sometimes considered invasive procedures such as inserting gastrostomies, draining pleural effusions or ascites, or even giving blood transfusions.
With the establishment of palliative medicine as a specialty has come a welcome increase in the use of some procedures and a less welcome feeling of need to develop technology to justify specialty status. Some invasive techniques such as epidural, intrathecal and intraventricular administration of opioid and other drugs are commonly reported.3,4 There are indications cited for using these techniqueS5 but in some situations their use is questionable, and the most recent advances in the management of chronic pain have been due to better understanding and more efficient use of established treatments rather than the development of new treatments. 6 Oral administration of drugs is considered the route of choice, with the rectal route the traditional alternative. There is however a reluctance to administer drugs rectally, and it is often stated that patients do not like to have drugs by this route, although the extent to which this reflects the true view of patients is unknown.S ubcutaneous administration of diamorphine was described for the control of advanced cancer pain in 1979.8 Continuous subcutaneous infusion followed, allowing the simultaneous use of opioids with anti-emetics, antispasmodic drugs, sedatives and neuroleptic drugs9; newer drugs which have been added to the list of those already used include midazolami° and ketorolac.ll With this has come the problem of duplicate prescribing which has been highlighted recently.12,13 The time has now come for a critical appraisal of drug administration for symptomatic measures in those with advanced cancer and particularly in those close to death.
The most common infusion device used in the UK is a syringe driver, but more sophisticated devices allowing patient controlled bolus injections have been used in some centres, including use in patients at home.14 Intractable vomiting, dysphagia or severe weakness preventing swallowing of drugs are the indications most commonly cited for the use of syringe drivers, but in practice the reasons for prescribing a drug or administering it by syringe driver are frequently not recorded in patients' notes.
It is difficult to find reliable data on the use of subcutaneous infusions of drugs. A retrospective survey at St Christopher's Hospice showed that in 1983 a syringe driver was used to administer medication for 34 patients (5% of admissions). 15 By contrast, in 1986, at any one time 30% of inpatients at St Columba's Hospice, Edinburgh, were using syringe driversl6 and some argue that about 70% of patients would benefit from an alternative (non-oral) route of opioid administration for hours to months before death. This contrasts with data from one hospicel8 where 60% of patients were able to swallow until a few hours before death and needed no change of route for drug administration. Another 25% required one or two doses of opioid by suppository; only 15% needed an injection. In a recent survey7 1276 (42%) of a total of 3013 patients were found to have used a syringe driver. These patients used syringe drivers for a total of 7382 days (mean 5.8). In addition, 100 patients used two drivers concurrently for a total of 540 days (mean 5.4); a total of 18 different drugs were recorded as being used in syringe drivers during the study period. Combinations of two drugs were used in 66% of prescriptions, the most popular combination being diamorphine and haloperidol. Fear of cancer, and in particular fear of death from cancer, is often associated with the fear of pain. Education in the principles of palliative care has reduced the number of patients dying in severe pain, but we must ensure that there is no tendency to overtreatment with its attendant risk of a higher incidence of adverse effects. It is becoming increasingly difficult to die at home, in hospital or in a specialist palliative care unit without having a syringe driver. It has been suggested that in patients close to death, with deteriorating renal function, the duration of action of sustained release preparations of morphine may be lengthened because of reduced renal clearance of morphine.19 With the introduction of novel methods of administration of opioids, such as the transdermal route ,20 this will allow a further option for analgesia and reduce the need for a change in the method of delivery of drugs in patients close to death. The ethos of hospice medicine sometimes prevents a critical appraisal of what we do. As the medicalization of birth has been questioned so must we now question the medicalization of death.
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